Logo image of PATH

UIPATH INC - CLASS A (PATH) Stock Fundamental Analysis

NYSE:PATH - New York Stock Exchange, Inc. - US90364P1057 - Common Stock - Currency: USD

12.24  -0.42 (-3.32%)

After market: 12.3 +0.06 (+0.49%)

Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to PATH. PATH was compared to 284 industry peers in the Software industry. While PATH has a great health rating, there are worries on its profitability. PATH is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year PATH was profitable.
In the past year PATH had a positive cash flow from operations.
In the past 5 years PATH always reported negative net income.
In multiple years PATH reported negative operating cash flow during the last 5 years.
PATH Yearly Net Income VS EBIT VS OCF VS FCFPATH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 2025 0 200M -200M -400M

1.2 Ratios

PATH's Return On Assets of -2.55% is in line compared to the rest of the industry. PATH outperforms 57.75% of its industry peers.
PATH's Return On Equity of -3.97% is fine compared to the rest of the industry. PATH outperforms 61.27% of its industry peers.
Industry RankSector Rank
ROA -2.55%
ROE -3.97%
ROIC N/A
ROA(3y)-5.87%
ROA(5y)-9.74%
ROE(3y)-8.52%
ROE(5y)-15%
ROIC(3y)N/A
ROIC(5y)N/A
PATH Yearly ROA, ROE, ROICPATH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 2025 -50 -100 -150 -200 -250

1.3 Margins

Looking at the Gross Margin, with a value of 82.62%, PATH belongs to the top of the industry, outperforming 90.49% of the companies in the same industry.
PATH's Gross Margin has been stable in the last couple of years.
PATH does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 82.62%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.76%
GM growth 5Y0.08%
PATH Yearly Profit, Operating, Gross MarginsPATH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 2025 0 50 -50 -100 -150

More info and screens

8

2. Health

2.1 Basic Checks

PATH does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, PATH has less shares outstanding
The number of shares outstanding for PATH has been increased compared to 5 years ago.
There is no outstanding debt for PATH. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
PATH Yearly Shares OutstandingPATH Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M
PATH Yearly Total Debt VS Total AssetsPATH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B 2.5B

2.2 Solvency

PATH has an Altman-Z score of 4.14. This indicates that PATH is financially healthy and has little risk of bankruptcy at the moment.
PATH's Altman-Z score of 4.14 is fine compared to the rest of the industry. PATH outperforms 66.55% of its industry peers.
There is no outstanding debt for PATH. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 4.14
ROIC/WACCN/A
WACC9.05%
PATH Yearly LT Debt VS Equity VS FCFPATH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 2025 0 500M 1B 1.5B 2B

2.3 Liquidity

A Current Ratio of 2.95 indicates that PATH has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 2.95, PATH is in the better half of the industry, outperforming 76.41% of the companies in the same industry.
A Quick Ratio of 2.95 indicates that PATH has no problem at all paying its short term obligations.
The Quick ratio of PATH (2.95) is better than 77.46% of its industry peers.
Industry RankSector Rank
Current Ratio 2.95
Quick Ratio 2.95
PATH Yearly Current Assets VS Current LiabilitesPATH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B 2.5B

More info and screens

6

3. Growth

3.1 Past

The earnings per share for PATH have decreased by -7.14% in the last year.
The Earnings Per Share has been growing by 88.99% on average over the past years. This is a very strong growth
The Revenue has been growing slightly by 7.21% in the past year.
PATH shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 33.58% yearly.
EPS 1Y (TTM)-7.14%
EPS 3Y88.99%
EPS 5YN/A
EPS Q2Q%-15.38%
Revenue 1Y (TTM)7.21%
Revenue growth 3Y17.01%
Revenue growth 5Y33.58%
Sales Q2Q%6.42%

3.2 Future

Based on estimates for the next years, PATH will show a small growth in Earnings Per Share. The EPS will grow by 1.84% on average per year.
PATH is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 11.61% yearly.
EPS Next Y1.85%
EPS Next 2Y5.71%
EPS Next 3Y7.03%
EPS Next 5Y1.84%
Revenue Next Year8.42%
Revenue Next 2Y8.57%
Revenue Next 3Y8.58%
Revenue Next 5Y11.61%

3.3 Evolution

The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
PATH Yearly Revenue VS EstimatesPATH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 500M 1B 1.5B 2B 2.5B
PATH Yearly EPS VS EstimatesPATH Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0.2 0.4 0.6

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

PATH is valuated rather expensively with a Price/Earnings ratio of 23.54.
Based on the Price/Earnings ratio, PATH is valued a bit cheaper than 75.35% of the companies in the same industry.
PATH's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 26.31.
The Price/Forward Earnings ratio is 20.28, which indicates a rather expensive current valuation of PATH.
PATH's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. PATH is cheaper than 72.54% of the companies in the same industry.
PATH is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 22.13, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 23.54
Fwd PE 20.28
PATH Price Earnings VS Forward Price EarningsPATH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, PATH is valued cheaper than 80.63% of the companies in the same industry.
Industry RankSector Rank
P/FCF 20.92
EV/EBITDA N/A
PATH Per share dataPATH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 1 2 3

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates PATH does not grow enough to justify the current Price/Earnings ratio.
PEG (NY)12.74
PEG (5Y)N/A
EPS Next 2Y5.71%
EPS Next 3Y7.03%

More info and screens

0

5. Dividend

5.1 Amount

PATH does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

UIPATH INC - CLASS A

NYSE:PATH (6/13/2025, 8:04:01 PM)

After market: 12.3 +0.06 (+0.49%)

12.24

-0.42 (-3.32%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupSoftware & Services
GICS IndustrySoftware
Earnings (Last)05-29 2025-05-29/amc
Earnings (Next)09-03 2025-09-03/amc
Inst Owners72.77%
Inst Owner Change4.31%
Ins Owners8.35%
Ins Owner Change0.25%
Market Cap6.55B
Analysts65.81
Price Target13.94 (13.89%)
Short Float %10.8%
Short Ratio3.4
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)17.23%
Min EPS beat(2)7.36%
Max EPS beat(2)27.1%
EPS beat(4)4
Avg EPS beat(4)25.4%
Min EPS beat(4)7.36%
Max EPS beat(4)47.41%
EPS beat(8)8
Avg EPS beat(8)46.66%
EPS beat(12)12
Avg EPS beat(12)102.69%
EPS beat(16)16
Avg EPS beat(16)98.69%
Revenue beat(2)1
Avg Revenue beat(2)1.34%
Min Revenue beat(2)-2.36%
Max Revenue beat(2)5.03%
Revenue beat(4)3
Avg Revenue beat(4)1.19%
Min Revenue beat(4)-2.36%
Max Revenue beat(4)5.03%
Revenue beat(8)5
Avg Revenue beat(8)1%
Revenue beat(12)9
Avg Revenue beat(12)2.32%
Revenue beat(16)13
Avg Revenue beat(16)2.65%
PT rev (1m)14.26%
PT rev (3m)-13.22%
EPS NQ rev (1m)25.92%
EPS NQ rev (3m)23.44%
EPS NY rev (1m)0%
EPS NY rev (3m)4.88%
Revenue NQ rev (1m)4.2%
Revenue NQ rev (3m)3.51%
Revenue NY rev (1m)1.67%
Revenue NY rev (3m)-2.1%
Valuation
Industry RankSector Rank
PE 23.54
Fwd PE 20.28
P/S 4.51
P/FCF 20.92
P/OCF 19.28
P/B 3.85
P/tB 4.22
EV/EBITDA N/A
EPS(TTM)0.52
EY4.25%
EPS(NY)0.6
Fwd EY4.93%
FCF(TTM)0.59
FCFY4.78%
OCF(TTM)0.63
OCFY5.19%
SpS2.71
BVpS3.18
TBVpS2.9
PEG (NY)12.74
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -2.55%
ROE -3.97%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 82.62%
FCFM 21.57%
ROA(3y)-5.87%
ROA(5y)-9.74%
ROE(3y)-8.52%
ROE(5y)-15%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.76%
GM growth 5Y0.08%
F-Score6
Asset Turnover0.55
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA N/A
Cap/Depr 170.17%
Cap/Sales 1.83%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.95
Quick Ratio 2.95
Altman-Z 4.14
F-Score6
WACC9.05%
ROIC/WACCN/A
Cap/Depr(3y)82.11%
Cap/Depr(5y)72.19%
Cap/Sales(3y)1.29%
Cap/Sales(5y)1.17%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-7.14%
EPS 3Y88.99%
EPS 5YN/A
EPS Q2Q%-15.38%
EPS Next Y1.85%
EPS Next 2Y5.71%
EPS Next 3Y7.03%
EPS Next 5Y1.84%
Revenue 1Y (TTM)7.21%
Revenue growth 3Y17.01%
Revenue growth 5Y33.58%
Sales Q2Q%6.42%
Revenue Next Year8.42%
Revenue Next 2Y8.57%
Revenue Next 3Y8.58%
Revenue Next 5Y11.61%
EBIT growth 1Y38.71%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year44.08%
EBIT Next 3Y23.71%
EBIT Next 5Y22.63%
FCF growth 1Y232.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y208.1%
OCF growth 3YN/A
OCF growth 5YN/A